Definitive Contract 75N91025C00051
Award Date
9/15/25
Potential Completion Date
9/14/27
Potential Value
$3M
Federal Agency
National Cancer Institute
Awardee
Novomedix LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92126, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
Novomedix LLC, a woman-owned small business, has been awarded a $355,000 firm fixed price contract from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to perform research and development on novel small molecules for the treatment of rhabdomyosarcoma, a rare cancer affecting muscle tissue. This is a Small Business Innovation Research (SBIR) concept award, which is a set-aside for small businesses. The contract has an ultimate completion date of June...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a civilian agency, to Nomocan Pharmaceuticals LLC, a for-profit limited liability company located in New York. The contract is for the development of therapeutic or preventative technologies for the treatment or prevention of pediatric cancers and/or rare cancers. The contract has a total ceiling value of $499,166.00 and a completion date of September 14, 2026. It is a firm...
This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Synbal, Inc., a small business located in La Costa, California. The contract, valued at $2,300,000.00, is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under the "MOONSHOT" initiative. The contract was set aside for small businesses...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This is a Small Business Innovation Research (SBIR) Phase I Concept Award from the National Cancer Institute (NCI), a civilian agency, to Tippingpoint Biosciences, Inc., a woman-owned small business. The $355,000 firm-fixed-price contract is for research and development activities to demonstrate technical feasibility and proof-of-concept for the development of innovative and potentially transformative therapeutic, device, diagnostic, or digital health technologies targeting Pediatric Cancers...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...